Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference

Published: Wednesday, March 20, 2013
Last Updated: Tuesday, March 19, 2013
Bookmark and Share
Laurent Levy to give a Company Presentation at the 20th Annual Future Leaders in New York.

Nanobiotix has announced that its co-founder and CEO, Laurent Levy, has been invited to give a Company Presentation at the 20th Annual Future Leaders in the Biotech Industry Conference in New York.

The Nanobiotix presentation is scheduled on Friday 5 April 2013 at 10:30 am ET in room 508 at the Millennium Hotel in New York, NY.

Laurent Levy will provide an overview of the Company’s strategy, technology and pipeline including its NanoXray technology, which has been developed to enhance radiotherapy energy to destroy tumor cells while not causing additional damage to the healthy surrounding tissue.

Following the presentation there will be a breakout session from 11:00am - 11:30am ET, in room 507.

The conference, which is co-hosted by BioCentury and Thomson Reuters, invites companies in key therapeutic areas to present a 25-minute company overview to leading portfolio managers, bankers and analysts. Nanobiotix is one of the few European Companies invited to present.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply
Mr Otin will be responsible for the manufacturing plans to move NBTXR3 from clinical trials.
Thursday, April 17, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress
Company announces its prospective financial communications calendar for the fiscal year 2014.
Friday, January 10, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.
Friday, July 05, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
NANOBIOTIX Announced Positive Phase I Results of NBTXR3
Company’s NBTXR3 achieves clinical milestone reaching proof-of-concept in phase I trial of STS.
Tuesday, June 04, 2013
Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award
Nanobiotix announces that its CEO and co-founder, Dr. Laurent Levy, has received the award at the Annual Inventors and Entrepreneurs Reception at the University at Buffalo (UB).
Thursday, April 04, 2013
Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board
Former Global Oncology Head from Sanofi-Aventis joins the Nanobiotix team.
Thursday, February 14, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Core-Shell Columns in HPLC: Food Analysis Applications
Explore the most recent applications of core-shell columns in food analysis.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!